Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program
January 10 2022 - 8:00AM
Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics, today announced Broad
Commercial Release of its Proteograph Product Suite and the launch
of its Centers of Excellence program. The Proteograph Product Suite
provides unprecedented access to the proteome in an unbiased way,
and at a scale comparable to what next-generation sequencing has
provided in genomics. The solution leverages proprietary engineered
nanoparticles to create a first-of-its-kind product that enables
unbiased, deep, and rapid proteomics at scale. Seer has already
received multiple Broad Release orders for the Proteograph Product
Suite.
“At Seer, we are passionate about empowering our customers to
decode the secrets of the proteome so that we can really begin to
understand biology in a functional and dynamic way. We are seeing
this firsthand with our Collaboration and Limited Release customers
who have had access to our product over the course of the past
year,” said Omid Farokhzad, CEO and Founder of Seer. “The
Proteograph Product Suite enables researchers to survey the full
dynamic range of the proteome with peptide-level resolution, a
fully automated workflow and extremely high precision, which allows
deep, unbiased proteomics studies at an unprecedented scale and
speed. We are very excited to now offer this powerful technology
broadly.”
Proteograph Product Suite
The Proteograph Product Suite includes Seer’s proprietary
engineered nanoparticles, consumables, an automation instrument,
and software that enables proteomics studies with an unprecedented
combination of speed, scale, depth and breadth of data. Seer’s
proprietary engineered nanoparticles deliver reproducible
performance across samples, labs, and experiments. The process is
fully automated, taking 7 hours, with only 30 minutes of hands-on
time, greatly simplifying workflow and reducing the complexity of a
traditional proteomics lab to a 96-well plate – where 16 samples
can be run in parallel. The accompanying Proteograph Analysis Suite
offers cloud-scalable software for proteomic data analysis,
visualization, and generation of biological insights. The
Proteograph Product Suite is detector agnostic and can be used with
virtually any mass spectrometer, making it even easier to add
unbiased, deep, rapid proteomics studies at scale to any lab.
Centers of Excellence Program
Seer has partnered with select leading service providers
world-wide to accelerate the adoption of unbiased, deep proteomics
at scale by making it easier for customers to access the value of
the Proteograph Product Suite for their projects. Seer Centers of
Excellence have been selected for their demonstrated expertise in
proteomics and multi-omics, their ability to deliver the highest
quality service, and their commitment to providing product and
workflow feedback to help expand the ecosystem around the
Proteograph Product Suite.
Seer Centers of Excellence are in various stages of
commercializing their services using the Proteograph Product Suite,
with providers in North America, Europe, and Asia Pacific
geographies, including:
- Biodesix: a leading
data-driven diagnostic solutions company
- Discovery Life
Sciences: a global leader in biomarker development and biospecimen
solutions utilizing proteomic, genomic, cell, and
immunohistochemistry (IHC) technologies
- Evotec: a global
platform company, leveraging its data-driven multimodality platform
for both proprietary as well as partnered research
- Sanford Burnham
Prebys Medical Discovery Institute: a state-of-the-art mass
spectrometry-based proteomics services core
- Soulbrain: a company
creating a better world through healthcare innovation
Biodesix, the first to join the Centers of Excellence program,
has leveraged the Proteograph in the development and validation of
a deep, unbiased proteomics workflow. “Biodesix is proud to have
been selected as the Seer Center of Excellence for biopharma
services and commercialization,” said Paul Beresford, CEO,
Biodesix. “We bring a wealth of knowledge with over 15 years of
experience using proteomics within our own laboratory and are truly
excited and ready to provide diagnostic solutions and access to the
Seer platform for biopharma partners.”
More information on the Seer Centers of Excellence Program can
be found at www.seer.bio/COE.
Seer is now accepting orders for the Proteograph Product Suite
and certain Centers of Excellence partners are also ready to
support service projects. For more information, visit
www.seer.bio.
About Seer
Seer is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph™ Product Suite is an integrated solution that
includes proprietary engineered nanoparticles, consumables,
automation instrumentation and software to perform deep, unbiased
proteomic analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Seer’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Seer’s actual results, performance, or
achievements to be materially different from those expressed or
implied by the forward-looking statements. These statements include
but are not limited to statements regarding Seer’s ability to
successfully execute the development and commercialization of its
Proteograph or the combined solution offered by the Consortium
agreement, the capacity to analyze and catalog more than one
billion peptides each year, the discovery of new protein variants,
novel biomarkers leading to therapeutic breakthroughs, the
ability of the combined product offering to enable labs to perform
unbiased, deep proteomics studies at scale to deliver new levels of
insight, speed, and sensitivity, to expand unbiased proteomics
discovery efforts, expand application sets, and future
collaborations. These and other risks are described more fully in
Seer’s filings with the Securities and Exchange Commission (“SEC”)
and other documents that Seer subsequently files with the SEC from
time to time. Except to the extent required by law, Seer undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made.
Seer Media Contact:
pr@seer.bio
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5c38d55f-38d8-4697-972f-c43504e43152
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024